Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06499285 · ClinicalTrials.gov registry record · Phase 3
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
A Phase 3 study of Myelodysplastic Syndromes, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 20
- Study locations
NCT06499285: Recruiting Phase 3 study of Myelodysplastic Syndromes, sponsored by Takeda.
NCT06499285 is a Phase 3 study of Myelodysplastic Syndromes that is actively recruiting participants, run by Takeda. The registered enrollment target is 225 participants, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06499285, a Phase 3 study of Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.
Primary Outcome
Transfusion independence is defined as the absence of any red blood cells (RBC) transfusions in a period of at least 8 weeks after the first dose of the study treatment through week 24.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Elritercept
Study Locations (20)
California
- City of Hope - Duarte
- Los Angeles Cancer Network - Glendale
- UC San Diego Moores Cancer Center - La Jolla
Tennessee
- Tennessee Cancer Specialists - Knoxville
- Baptist Clinical Research Institute - Memphis
- Vanderbilt University Medical Center - Nashville
Texas
- Texas Oncology Northeast Texas - Denison
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine - Houston
- Texas Oncology Gulf Coast - The Woodlands
Florida
- University of Miami Hospital and Clinics - Miami
- Moffitt Cancer Center - Tampa
Maryland
- Johns Hopkins Hospital - Baltimore
- Maryland Oncology Hematolofy - Columbia
Ohio
- Gabrail Cancer Center Research - Canton
- Cleveland Clinic - Cleveland - Cleveland
Connecticut
- Smilow Cancer Hospital at Yale-New Haven - New Haven
Illinois
- ILCC. Illinois Cancer Centers - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2032-05-01 |
| Phase | Phase 3 |
What NCT06499285 shows while recruiting
NCT06499285 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06499285 names 20 study sites across 11 states, led by California, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT06499285 about?
NCT06499285 is a clinical study titled "A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions". The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check...
What is the current status of trial NCT06499285?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2025-05-06. Estimated completion is 2032-05-01.
What conditions does trial NCT06499285 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes.
What interventions are being tested in trial NCT06499285?
The interventions under investigation include: Placebo (DRUG), Elritercept (DRUG).
Who is sponsoring clinical trial NCT06499285?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06499285 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06499285's enrollment target sits among peer trials
225 29th of 173 higher than 144 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
RECRUITING · Phase 3
-
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
ACTIVE NOT RECRUITING · Phase 3
-
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI